Regulatory approval

Published by the Health Service Executive. Approved

Quizartinib in combination with standard IDArubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Quizartinib - CDS; idarubicin and cytarabine - N/A

Citation

Quizartinib, IDArubicin and Cytarabine Induction Therapy, 2026, version number 2, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7020/891_Quizartinib_Induction_IDArubicin.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2025-02-01	Health Service Executive	Indication approved for reimbursement.